Search

Your search keyword '"Clanet, Michel"' showing total 258 results

Search Constraints

Start Over You searched for: Author "Clanet, Michel" Remove constraint Author: "Clanet, Michel"
258 results on '"Clanet, Michel"'

Search Results

1. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

6. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

7. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

9. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

10. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

12. Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients

13. Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease

16. Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification

17. Investigation of seven proposed regions of linkage in multiple sclerosis: an American and French collaborative study

18. Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy

20. Increased risk of multiple sclerosis relapse after in vitro fertilisation

21. Long-term Outcomes of CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids) in a Consecutive Series of 12 Patients

22. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

23. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

24. Evaluation of O-(2-[18F]-Fluoroethyl)-L-Tyrosine in the Diagnosis of Glioblastoma

26. Biallelic MYORG mutation carriers exhibit primary brain calcification with a distinct phenotype

27. Additional file 2: of MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

28. Additional file 1: of MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

29. Natural History of Multiple Sclerosis with Childhood Onset

35. MSJ815602_Annex_1 – Supplemental material for Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France

36. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France

37. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

41. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

44. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

46. Geographical Heterogeneity of Multiple Sclerosis Prevalence in France

47. Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study (S49.005)

48. 24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase (S49.004)

Catalog

Books, media, physical & digital resources